$AEGR Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Aegerion Pharmaceuticals, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Aegerion Pharmaceuticals, Inc.. Get notifications about new insider transactions in Aegerion Pharmaceuticals, Inc. for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jan 05 2015 | AEGR | Aegerion Pharmaceu ... | Fitzpatrick Mark J. | Chief Financial Off ... | Option Exercise | A | 15.95 | 65,000 | 1,036,750 | 65,000 | |
Jan 05 2015 | AEGR | Aegerion Pharmaceu ... | Beer Marc D | Chief Executive Off ... | Option Exercise | A | 15.95 | 120,000 | 1,914,000 | 120,000 | |
Jan 05 2015 | AEGR | Aegerion Pharmaceu ... | Sumeray Mark | Chief Medical Offic ... | Option Exercise | A | 15.95 | 65,000 | 1,036,750 | 65,000 | |
Jan 05 2015 | AEGR | Aegerion Pharmaceu ... | Carter Martha J. | See Remarks | Option Exercise | A | 15.95 | 65,000 | 1,036,750 | 65,000 | |
Jan 05 2015 | AEGR | Aegerion Pharmaceu ... | Fraser Craig | Chief Operating Off ... | Option Exercise | A | 15.95 | 45,000 | 717,750 | 45,000 | |
Sep 02 2014 | AEGR | Aegerion Pharmaceu ... | Beer Marc D | Chief Executive Off ... | Gift | G | 0.00 | 769 | 0 | 78,631 | 79.4 K to 78.6 K (-0.97 %) |
Aug 20 2014 | AEGR | Aegerion Pharmaceu ... | Fitzpatrick Mark J. | Chief Financial Off ... | Buy | P | 30.64 | 1,150 | 35,236 | 9,500 | 8.4 K to 9.5 K (+13.77 %) |
Aug 04 2014 | AEGR | Aegerion Pharmaceu ... | Fraser Craig | Chief Operating Off ... | Option Exercise | A | 33.22 | 50,000 | 1,661,000 | 50,000 | |
Jul 31 2014 | AEGR | Aegerion Pharmaceu ... | Beer Marc D | Chief Executive Off ... | Buy | P | 34.37 | 2,300 | 79,051 | 79,400 | 77.1 K to 79.4 K (+2.98 %) |
Jul 31 2014 | AEGR | Aegerion Pharmaceu ... | Beer Marc D | Chief Executive Off ... | Buy | P | 33.44 | 7,700 | 257,488 | 77,100 | 69.4 K to 77.1 K (+11.10 %) |
Jun 30 2014 | AEGR | Aegerion Pharmaceu ... | GOTTO ANTONIO M JR MD D PHIL | Director | Option Exercise | A | 32.55 | 5,012 | 163,141 | 5,012 | |
Jun 30 2014 | AEGR | Aegerion Pharmaceu ... | BARER SOL J | Director | Option Exercise | A | 32.55 | 5,012 | 163,141 | 5,012 | |
Jun 30 2014 | AEGR | Aegerion Pharmaceu ... | Scheer David | Director | Option Exercise | A | 32.55 | 5,012 | 163,141 | 5,012 | |
Jun 30 2014 | AEGR | Aegerion Pharmaceu ... | VANLENT ANNE | Director | Option Exercise | A | 32.55 | 5,012 | 163,141 | 5,012 | |
Jun 30 2014 | AEGR | Aegerion Pharmaceu ... | THOMAS PAUL | Director | Option Exercise | A | 32.55 | 5,012 | 163,141 | 5,012 | |
Jun 04 2014 | AEGR | Aegerion Pharmaceu ... | Beer Marc D | Chief Executive Off ... | Buy | P | 30.12 | 10,000 | 301,200 | 69,400 | 59.4 K to 69.4 K (+16.84 %) |
Jun 30 2014 | AEGR | Aegerion Pharmaceu ... | SMITH SANDFORD D | Director | Option Exercise | A | 32.55 | 5,012 | 163,141 | 5,012 | |
May 22 2014 | AEGR | Aegerion Pharmaceu ... | Beer Marc D | Chief Executive Off ... | Option Exercise | M | 1.54 | 6,400 | 9,856 | 732,873 | |
May 22 2014 | AEGR | Aegerion Pharmaceu ... | Beer Marc D | Chief Executive Off ... | Buy | M | 1.54 | 6,400 | 9,856 | 49,400 | 43 K to 49.4 K (+14.88 %) |
May 27 2014 | AEGR | Aegerion Pharmaceu ... | Beer Marc D | Chief Executive Off ... | Buy | P | 31.59 | 10,000 | 315,900 | 59,400 | 49.4 K to 59.4 K (+20.24 %) |
May 21 2014 | AEGR | Aegerion Pharmaceu ... | Beer Marc D | Chief Executive Off ... | Buy | P | 30.53 | 10,000 | 305,300 | 43,000 | 33 K to 43 K (+30.30 %) |
May 09 2014 | AEGR | Aegerion Pharmaceu ... | VANLENT ANNE | Director | Buy | P | 35.29 | 52 | 1,835 | 4,000 | 3.9 K to 4 K (+1.32 %) |
May 09 2014 | AEGR | Aegerion Pharmaceu ... | VANLENT ANNE | Director | Buy | P | 34.33 | 1,948 | 66,875 | 3,948 | 2 K to 3.9 K (+97.40 %) |
May 09 2014 | AEGR | Aegerion Pharmaceu ... | VANLENT ANNE | Director | Buy | P | 33.20 | 2,000 | 66,400 | 2,000 | 0 to 2 K |
May 08 2014 | AEGR | Aegerion Pharmaceu ... | Beer Marc D | Chief Executive Off ... | Buy | P | 35.31 | 30,000 | 1,059,300 | 33,000 | 3 K to 33 K (+1,000.00 %) |
May 01 2014 | AEGR | Aegerion Pharmaceu ... | Fraser Craig | Pres., US/Int. Comm ... | Option Exercise | M | 13.01 | 2,250 | 29,273 | 66,500 | |
May 01 2014 | AEGR | Aegerion Pharmaceu ... | Fraser Craig | Pres., US/Int. Comm ... | Sell | S | 43.90 | 1,171 | 51,407 | 0 | 1.2 K to 0 (-100.00 %) |
May 01 2014 | AEGR | Aegerion Pharmaceu ... | Fraser Craig | Pres., US/Int. Comm ... | Sell | S | 43.18 | 1,079 | 46,591 | 1,171 | 2.3 K to 1.2 K (-47.96 %) |
May 01 2014 | AEGR | Aegerion Pharmaceu ... | Fraser Craig | Pres., US/Int. Comm ... | Buy | M | 13.01 | 2,250 | 29,273 | 2,250 | 0 to 2.3 K |
Apr 21 2014 | AEGR | Aegerion Pharmaceu ... | Sumeray Mark | Chief Medical Offic ... | Option Exercise | A | 47.11 | 20,000 | 942,200 | 20,000 | |
Apr 21 2014 | AEGR | Aegerion Pharmaceu ... | Fitzpatrick Mark J. | Chief Financial Off ... | Option Exercise | A | 47.11 | 20,000 | 942,200 | 20,000 | |
Apr 21 2014 | AEGR | Aegerion Pharmaceu ... | Beer Marc D | Chief Executive Off ... | Option Exercise | A | 47.11 | 75,000 | 3,533,250 | 75,000 | |
Apr 21 2014 | AEGR | Aegerion Pharmaceu ... | Carter Martha J. | See Remarks | Option Exercise | A | 47.11 | 13,000 | 612,430 | 13,000 | |
Apr 21 2014 | AEGR | Aegerion Pharmaceu ... | Fraser Craig | Pres., US/Int. Comm ... | Option Exercise | A | 47.11 | 20,000 | 942,200 | 20,000 | |
Apr 02 2014 | AEGR | Aegerion Pharmaceu ... | Fraser Craig | Pres., US/Int. Comm ... | Option Exercise | M | 13.01 | 2,250 | 29,273 | 68,750 | |
Apr 02 2014 | AEGR | Aegerion Pharmaceu ... | Fraser Craig | Pres., US/Int. Comm ... | Sell | S | 47.20 | 100 | 4,720 | 0 | 100 to 0 (-100.00 %) |
Apr 02 2014 | AEGR | Aegerion Pharmaceu ... | Fraser Craig | Pres., US/Int. Comm ... | Sell | S | 46.51 | 1,001 | 46,557 | 100 | 1.1 K to 100 (-90.92 %) |
Apr 02 2014 | AEGR | Aegerion Pharmaceu ... | Fraser Craig | Pres., US/Int. Comm ... | Sell | S | 45.84 | 1,149 | 52,670 | 1,101 | 2.3 K to 1.1 K (-51.07 %) |
Apr 02 2014 | AEGR | Aegerion Pharmaceu ... | Fraser Craig | Pres., US/Int. Comm ... | Buy | M | 13.01 | 2,250 | 29,273 | 2,250 | 0 to 2.3 K |
Apr 21 2014 | AEGR | Aegerion Pharmaceu ... | Cook Anne Marie | SVP, General Counse ... | Option Exercise | A | 47.11 | 13,000 | 612,430 | 13,000 | |
Mar 27 2014 | AEGR | Aegerion Pharmaceu ... | Beer Marc D | Chief Executive Off ... | Option Exercise | M | 1.54 | 3,000 | 4,620 | 739,273 | |
Mar 27 2014 | AEGR | Aegerion Pharmaceu ... | Beer Marc D | Chief Executive Off ... | Buy | M | 1.54 | 3,000 | 4,620 | 3,000 | 0 to 3 K |
Mar 18 2014 | AEGR | Aegerion Pharmaceu ... | Sumeray Mark | Chief Medical Offic ... | Option Exercise | M | 13.01 | 2,000 | 26,020 | 113,000 | |
Mar 18 2014 | AEGR | Aegerion Pharmaceu ... | Sumeray Mark | Chief Medical Offic ... | Sell | S | 51.98 | 800 | 41,584 | 0 | 800 to 0 (-100.00 %) |
Mar 18 2014 | AEGR | Aegerion Pharmaceu ... | Sumeray Mark | Chief Medical Offic ... | Sell | S | 51.31 | 900 | 46,179 | 800 | 1.7 K to 800 (-52.94 %) |
Mar 18 2014 | AEGR | Aegerion Pharmaceu ... | Sumeray Mark | Chief Medical Offic ... | Sell | S | 49.69 | 300 | 14,907 | 1,700 | 2 K to 1.7 K (-15.00 %) |
Mar 18 2014 | AEGR | Aegerion Pharmaceu ... | Sumeray Mark | Chief Medical Offic ... | Buy | M | 13.01 | 2,000 | 26,020 | 2,000 | 0 to 2 K |
Mar 05 2014 | AEGR | Aegerion Pharmaceu ... | Fitzpatrick Mark J. | Chief Financial Off ... | Option Exercise | M | 17.64 | 2,500 | 44,100 | 189,650 | |
Mar 05 2014 | AEGR | Aegerion Pharmaceu ... | Fitzpatrick Mark J. | Chief Financial Off ... | Buy | M | 17.64 | 2,500 | 44,100 | 8,350 | 5.9 K to 8.4 K (+42.74 %) |
Feb 12 2014 | AEGR | Aegerion Pharmaceu ... | Fitzpatrick Mark J. | Chief Financial Off ... | Option Exercise | M | 17.64 | 7,500 | 132,300 | 192,150 | |
Feb 12 2014 | AEGR | Aegerion Pharmaceu ... | Fitzpatrick Mark J. | Chief Financial Off ... | Sell | S | 64.69 | 486 | 31,439 | 5,850 | 6.3 K to 5.9 K (-7.67 %) |
Feb 12 2014 | AEGR | Aegerion Pharmaceu ... | Fitzpatrick Mark J. | Chief Financial Off ... | Sell | S | 63.72 | 900 | 57,348 | 6,336 | 7.2 K to 6.3 K (-12.44 %) |
Feb 12 2014 | AEGR | Aegerion Pharmaceu ... | Fitzpatrick Mark J. | Chief Financial Off ... | Sell | S | 62.94 | 2,814 | 177,113 | 7,236 | 10.1 K to 7.2 K (-28.00 %) |
Feb 12 2014 | AEGR | Aegerion Pharmaceu ... | Fitzpatrick Mark J. | Chief Financial Off ... | Sell | S | 61.71 | 3,300 | 203,643 | 10,050 | 13.4 K to 10.1 K (-24.72 %) |
Feb 12 2014 | AEGR | Aegerion Pharmaceu ... | Fitzpatrick Mark J. | Chief Financial Off ... | Buy | M | 17.64 | 7,500 | 132,300 | 13,350 | 5.9 K to 13.4 K (+128.21 %) |
Feb 18 2014 | AEGR | Aegerion Pharmaceu ... | Sumeray Mark | Chief Medical Offic ... | Option Exercise | M | 13.01 | 2,000 | 26,020 | 115,000 | |
Feb 18 2014 | AEGR | Aegerion Pharmaceu ... | Sumeray Mark | Chief Medical Offic ... | Sell | S | 64.52 | 500 | 32,260 | 0 | 500 to 0 (-100.00 %) |
Feb 18 2014 | AEGR | Aegerion Pharmaceu ... | Sumeray Mark | Chief Medical Offic ... | Sell | S | 63.14 | 1,500 | 94,710 | 500 | 2 K to 500 (-75.00 %) |
Feb 18 2014 | AEGR | Aegerion Pharmaceu ... | Sumeray Mark | Chief Medical Offic ... | Buy | M | 13.01 | 2,000 | 26,020 | 2,000 | 0 to 2 K |
Feb 12 2014 | AEGR | Aegerion Pharmaceu ... | Fraser Craig | Pres., US/Int. Comm ... | Option Exercise | M | 13.01 | 2,250 | 29,273 | 71,000 | |
Feb 12 2014 | AEGR | Aegerion Pharmaceu ... | Fraser Craig | Pres., US/Int. Comm ... | Sell | S | 67.00 | 2,250 | 150,750 | 0 | 2.3 K to 0 (-100.00 %) |
Feb 12 2014 | AEGR | Aegerion Pharmaceu ... | Fraser Craig | Pres., US/Int. Comm ... | Buy | M | 13.01 | 2,250 | 29,273 | 2,250 | 0 to 2.3 K |
Jan 21 2014 | AEGR | Aegerion Pharmaceu ... | Sumeray Mark | Chief Medical Offic ... | Option Exercise | M | 13.01 | 2,000 | 26,020 | 117,000 | |
Jan 21 2014 | AEGR | Aegerion Pharmaceu ... | Sumeray Mark | Chief Medical Offic ... | Sell | S | 59.51 | 100 | 5,951 | 0 | 100 to 0 (-100.00 %) |
Jan 21 2014 | AEGR | Aegerion Pharmaceu ... | Sumeray Mark | Chief Medical Offic ... | Sell | S | 58.59 | 1,900 | 111,318 | 100 | 2 K to 100 (-95.00 %) |
Jan 21 2014 | AEGR | Aegerion Pharmaceu ... | Sumeray Mark | Chief Medical Offic ... | Buy | M | 13.01 | 2,000 | 26,020 | 2,000 | 0 to 2 K |
Jan 06 2014 | AEGR | Aegerion Pharmaceu ... | Fraser Craig | Pres., US/Int. Comm ... | Option Exercise | M | 13.01 | 2,250 | 29,273 | 73,250 | |
Jan 06 2014 | AEGR | Aegerion Pharmaceu ... | Fraser Craig | Pres., US/Int. Comm ... | Sell | S | 71.42 | 1,350 | 96,414 | 0 | 1.4 K to 0 (-100.00 %) |
Jan 06 2014 | AEGR | Aegerion Pharmaceu ... | Fraser Craig | Pres., US/Int. Comm ... | Sell | S | 70.65 | 900 | 63,584 | 1,350 | 2.3 K to 1.4 K (-40.00 %) |
Jan 06 2014 | AEGR | Aegerion Pharmaceu ... | Fraser Craig | Pres., US/Int. Comm ... | Buy | M | 13.01 | 2,250 | 29,273 | 2,250 | 0 to 2.3 K |
Jan 06 2014 | AEGR | Aegerion Pharmaceu ... | Sumeray Mark | Chief Medical Offic ... | Option Exercise | M | 13.01 | 1,000 | 13,010 | 119,000 | |
Jan 06 2014 | AEGR | Aegerion Pharmaceu ... | Sumeray Mark | Chief Medical Offic ... | Sell | S | 71.41 | 600 | 42,847 | 0 | 600 to 0 (-100.00 %) |
Jan 06 2014 | AEGR | Aegerion Pharmaceu ... | Sumeray Mark | Chief Medical Offic ... | Sell | S | 70.22 | 400 | 28,087 | 600 | 1,000 to 600 (-40.00 %) |
Jan 06 2014 | AEGR | Aegerion Pharmaceu ... | Sumeray Mark | Chief Medical Offic ... | Buy | M | 13.01 | 1,000 | 13,010 | 1,000 | 0 to 1,000 |
Dec 17 2013 | AEGR | Aegerion Pharmaceu ... | Sumeray Mark | Chief Medical Offic ... | Option Exercise | M | 13.01 | 2,000 | 26,020 | 120,000 | |
Dec 17 2013 | AEGR | Aegerion Pharmaceu ... | Sumeray Mark | Chief Medical Offic ... | Sell | S | 67.38 | 200 | 13,476 | 0 | 200 to 0 (-100.00 %) |
Dec 17 2013 | AEGR | Aegerion Pharmaceu ... | Sumeray Mark | Chief Medical Offic ... | Sell | S | 66.23 | 1,800 | 119,211 | 200 | 2 K to 200 (-90.00 %) |
Dec 17 2013 | AEGR | Aegerion Pharmaceu ... | Sumeray Mark | Chief Medical Offic ... | Buy | M | 13.01 | 2,000 | 26,020 | 2,000 | 0 to 2 K |
Dec 06 2013 | AEGR | Aegerion Pharmaceu ... | Beer Marc D | Chief Executive Off ... | Option Exercise | M | 1.54 | 4,380 | 6,745 | 742,273 | |
Dec 06 2013 | AEGR | Aegerion Pharmaceu ... | Beer Marc D | Chief Executive Off ... | Gift | G | 0.00 | 4,380 | 0 | 0 | 4.4 K to 0 (-100.00 %) |
Dec 06 2013 | AEGR | Aegerion Pharmaceu ... | Beer Marc D | Chief Executive Off ... | Buy | M | 1.54 | 4,380 | 6,745 | 4,380 | 0 to 4.4 K |
Dec 04 2013 | AEGR | Aegerion Pharmaceu ... | Sumeray Mark | Chief Medical Offic ... | Option Exercise | M | 13.01 | 3,000 | 39,030 | 122,000 | |
Dec 04 2013 | AEGR | Aegerion Pharmaceu ... | Sumeray Mark | Chief Medical Offic ... | Sell | S | 71.20 | 600 | 42,718 | 0 | 600 to 0 (-100.00 %) |
Dec 04 2013 | AEGR | Aegerion Pharmaceu ... | Sumeray Mark | Chief Medical Offic ... | Sell | S | 70.23 | 2,400 | 168,549 | 600 | 3 K to 600 (-80.00 %) |
Dec 04 2013 | AEGR | Aegerion Pharmaceu ... | Sumeray Mark | Chief Medical Offic ... | Buy | M | 13.01 | 3,000 | 39,030 | 3,000 | 0 to 3 K |
Dec 04 2013 | AEGR | Aegerion Pharmaceu ... | Fraser Craig | Pres., US/Int. Comm ... | Option Exercise | M | 13.01 | 2,250 | 29,273 | 75,500 | |
Dec 04 2013 | AEGR | Aegerion Pharmaceu ... | Fraser Craig | Pres., US/Int. Comm ... | Sell | S | 71.10 | 700 | 49,769 | 0 | 700 to 0 (-100.00 %) |
Dec 04 2013 | AEGR | Aegerion Pharmaceu ... | Fraser Craig | Pres., US/Int. Comm ... | Sell | S | 70.10 | 1,550 | 108,654 | 700 | 2.3 K to 700 (-68.89 %) |
Dec 04 2013 | AEGR | Aegerion Pharmaceu ... | Fraser Craig | Pres., US/Int. Comm ... | Buy | M | 13.01 | 2,250 | 29,273 | 2,250 | 0 to 2.3 K |
Nov 19 2013 | AEGR | Aegerion Pharmaceu ... | Sumeray Mark | Chief Medical Offic ... | Option Exercise | M | 13.01 | 2,000 | 26,020 | 125,000 | |
Nov 19 2013 | AEGR | Aegerion Pharmaceu ... | Sumeray Mark | Chief Medical Offic ... | Sell | S | 77.63 | 500 | 38,817 | 0 | 500 to 0 (-100.00 %) |
Nov 19 2013 | AEGR | Aegerion Pharmaceu ... | Sumeray Mark | Chief Medical Offic ... | Sell | S | 75.89 | 1,011 | 76,726 | 500 | 1.5 K to 500 (-66.91 %) |
Nov 19 2013 | AEGR | Aegerion Pharmaceu ... | Sumeray Mark | Chief Medical Offic ... | Sell | S | 74.93 | 489 | 36,639 | 1,511 | 2 K to 1.5 K (-24.45 %) |
Nov 19 2013 | AEGR | Aegerion Pharmaceu ... | Sumeray Mark | Chief Medical Offic ... | Buy | M | 13.01 | 2,000 | 26,020 | 2,000 | 0 to 2 K |
Nov 13 2013 | AEGR | Aegerion Pharmaceu ... | Fitzpatrick Mark J. | Chief Financial Off ... | Option Exercise | M | 17.64 | 2,850 | 50,274 | 199,650 | |
Nov 13 2013 | AEGR | Aegerion Pharmaceu ... | Fitzpatrick Mark J. | Chief Financial Off ... | Option Exercise | M | 17.64 | 7,500 | 132,300 | 202,500 | |
Nov 13 2013 | AEGR | Aegerion Pharmaceu ... | Fitzpatrick Mark J. | Chief Financial Off ... | Buy | M | 17.64 | 2,850 | 50,274 | 5,850 | 3 K to 5.9 K (+95.00 %) |
Nov 13 2013 | AEGR | Aegerion Pharmaceu ... | Fitzpatrick Mark J. | Chief Financial Off ... | Sell | S | 80.03 | 1,800 | 144,057 | 3,000 | 4.8 K to 3 K (-37.50 %) |
Nov 13 2013 | AEGR | Aegerion Pharmaceu ... | Fitzpatrick Mark J. | Chief Financial Off ... | Sell | S | 79.34 | 4,478 | 355,300 | 4,800 | 9.3 K to 4.8 K (-48.26 %) |
Nov 13 2013 | AEGR | Aegerion Pharmaceu ... | Fitzpatrick Mark J. | Chief Financial Off ... | Sell | S | 78.38 | 622 | 48,755 | 9,278 | 9.9 K to 9.3 K (-6.28 %) |
Nov 13 2013 | AEGR | Aegerion Pharmaceu ... | Fitzpatrick Mark J. | Chief Financial Off ... | Sell | S | 76.14 | 200 | 15,228 | 9,900 | 10.1 K to 9.9 K (-1.98 %) |
Nov 13 2013 | AEGR | Aegerion Pharmaceu ... | Fitzpatrick Mark J. | Chief Financial Off ... | Sell | S | 74.43 | 200 | 14,886 | 10,100 | 10.3 K to 10.1 K (-1.94 %) |
Nov 13 2013 | AEGR | Aegerion Pharmaceu ... | Fitzpatrick Mark J. | Chief Financial Off ... | Sell | S | 73.01 | 200 | 14,603 | 10,300 | 10.5 K to 10.3 K (-1.90 %) |
Nov 13 2013 | AEGR | Aegerion Pharmaceu ... | Fitzpatrick Mark J. | Chief Financial Off ... | Buy | M | 17.64 | 7,500 | 132,300 | 10,500 | 3 K to 10.5 K (+250.00 %) |
Nov 06 2013 | AEGR | Aegerion Pharmaceu ... | Beer Marc D | Chief Executive Off ... | Option Exercise | M | 1.54 | 39,000 | 60,060 | 746,653 | |
Nov 06 2013 | AEGR | Aegerion Pharmaceu ... | Beer Marc D | Chief Executive Off ... | Buy | M | 1.54 | 39,000 | 60,060 | 234,726 | 195.7 K to 234.7 K (+19.93 %) |
Nov 05 2013 | AEGR | Aegerion Pharmaceu ... | Carter Martha J. | Chief Regulatory Of ... | Option Exercise | M | 14.84 | 5,000 | 74,200 | 127,000 | |
Nov 05 2013 | AEGR | Aegerion Pharmaceu ... | Carter Martha J. | Chief Regulatory Of ... | Sell | S | 82.81 | 5,000 | 414,051 | 1,500 | 6.5 K to 1.5 K (-76.92 %) |
Nov 05 2013 | AEGR | Aegerion Pharmaceu ... | Carter Martha J. | Chief Regulatory Of ... | Buy | M | 14.84 | 5,000 | 74,200 | 6,500 | 1.5 K to 6.5 K (+333.33 %) |
Nov 05 2013 | AEGR | Aegerion Pharmaceu ... | Sumeray Mark | Chief Medical Offic ... | Option Exercise | M | 13.01 | 3,500 | 45,535 | 127,000 | |
Nov 05 2013 | AEGR | Aegerion Pharmaceu ... | Sumeray Mark | Chief Medical Offic ... | Sell | S | 84.34 | 100 | 8,434 | 0 | 100 to 0 (-100.00 %) |
Nov 05 2013 | AEGR | Aegerion Pharmaceu ... | Sumeray Mark | Chief Medical Offic ... | Sell | S | 83.59 | 2,000 | 167,180 | 100 | 2.1 K to 100 (-95.24 %) |
Nov 05 2013 | AEGR | Aegerion Pharmaceu ... | Sumeray Mark | Chief Medical Offic ... | Sell | S | 82.76 | 1,400 | 115,867 | 2,100 | 3.5 K to 2.1 K (-40.00 %) |
Nov 05 2013 | AEGR | Aegerion Pharmaceu ... | Sumeray Mark | Chief Medical Offic ... | Buy | M | 13.01 | 3,500 | 45,535 | 3,500 | 0 to 3.5 K |
Nov 05 2013 | AEGR | Aegerion Pharmaceu ... | Fraser Craig | Pres., US/Int. Comm ... | Option Exercise | M | 13.01 | 2,250 | 29,273 | 77,750 | |
Nov 05 2013 | AEGR | Aegerion Pharmaceu ... | Fraser Craig | Pres., US/Int. Comm ... | Sell | S | 83.99 | 400 | 33,597 | 0 | 400 to 0 (-100.00 %) |
Nov 05 2013 | AEGR | Aegerion Pharmaceu ... | Fraser Craig | Pres., US/Int. Comm ... | Sell | S | 83.22 | 1,550 | 128,994 | 400 | 2 K to 400 (-79.49 %) |
Nov 05 2013 | AEGR | Aegerion Pharmaceu ... | Fraser Craig | Pres., US/Int. Comm ... | Sell | S | 82.28 | 300 | 24,684 | 1,950 | 2.3 K to 2 K (-13.33 %) |
Nov 05 2013 | AEGR | Aegerion Pharmaceu ... | Fraser Craig | Pres., US/Int. Comm ... | Buy | M | 13.01 | 2,250 | 29,273 | 2,250 | 0 to 2.3 K |
Oct 31 2013 | AEGR | Aegerion Pharmaceu ... | Beer Marc D | Chief Executive Off ... | Option Exercise | M | 1.54 | 40,000 | 61,600 | 785,653 | |
Oct 31 2013 | AEGR | Aegerion Pharmaceu ... | Beer Marc D | Chief Executive Off ... | Sell | S | 99.18 | 1,200 | 119,016 | 195,726 | 196.9 K to 195.7 K (-0.61 %) |
Oct 31 2013 | AEGR | Aegerion Pharmaceu ... | Beer Marc D | Chief Executive Off ... | Sell | S | 95.90 | 300 | 28,770 | 196,926 | 197.2 K to 196.9 K (-0.15 %) |
Oct 31 2013 | AEGR | Aegerion Pharmaceu ... | Beer Marc D | Chief Executive Off ... | Sell | S | 94.25 | 200 | 18,850 | 197,226 | 197.4 K to 197.2 K (-0.10 %) |
Oct 31 2013 | AEGR | Aegerion Pharmaceu ... | Beer Marc D | Chief Executive Off ... | Sell | S | 93.00 | 400 | 37,200 | 197,426 | 197.8 K to 197.4 K (-0.20 %) |
Oct 31 2013 | AEGR | Aegerion Pharmaceu ... | Beer Marc D | Chief Executive Off ... | Sell | S | 92.03 | 700 | 64,421 | 197,826 | 198.5 K to 197.8 K (-0.35 %) |
Oct 31 2013 | AEGR | Aegerion Pharmaceu ... | Beer Marc D | Chief Executive Off ... | Sell | S | 91.21 | 2,500 | 228,031 | 198,526 | 201 K to 198.5 K (-1.24 %) |
Oct 31 2013 | AEGR | Aegerion Pharmaceu ... | Beer Marc D | Chief Executive Off ... | Sell | S | 89.85 | 2,700 | 242,592 | 201,026 | 203.7 K to 201 K (-1.33 %) |
Oct 31 2013 | AEGR | Aegerion Pharmaceu ... | Beer Marc D | Chief Executive Off ... | Sell | S | 89.01 | 3,800 | 338,243 | 203,726 | 207.5 K to 203.7 K (-1.83 %) |
Oct 31 2013 | AEGR | Aegerion Pharmaceu ... | Beer Marc D | Chief Executive Off ... | Sell | S | 87.83 | 6,019 | 528,619 | 207,526 | 213.5 K to 207.5 K (-2.82 %) |
Oct 31 2013 | AEGR | Aegerion Pharmaceu ... | Beer Marc D | Chief Executive Off ... | Sell | S | 87.08 | 10,000 | 870,752 | 213,545 | 223.5 K to 213.5 K (-4.47 %) |
Oct 31 2013 | AEGR | Aegerion Pharmaceu ... | Beer Marc D | Chief Executive Off ... | Sell | S | 85.94 | 2,314 | 198,860 | 223,545 | 225.9 K to 223.5 K (-1.02 %) |
Oct 31 2013 | AEGR | Aegerion Pharmaceu ... | Beer Marc D | Chief Executive Off ... | Sell | S | 85.00 | 7,067 | 600,689 | 225,859 | 232.9 K to 225.9 K (-3.03 %) |
Oct 31 2013 | AEGR | Aegerion Pharmaceu ... | Beer Marc D | Chief Executive Off ... | Sell | S | 84.15 | 2,800 | 235,621 | 232,926 | 235.7 K to 232.9 K (-1.19 %) |
Oct 31 2013 | AEGR | Aegerion Pharmaceu ... | Beer Marc D | Chief Executive Off ... | Buy | M | 1.54 | 40,000 | 61,600 | 235,726 | 195.7 K to 235.7 K (+20.44 %) |
Oct 31 2013 | AEGR | Aegerion Pharmaceu ... | SMITH SANDFORD D | Director | Option Exercise | M | 15.00 | 2,502 | 37,530 | 8,569 | |
Oct 31 2013 | AEGR | Aegerion Pharmaceu ... | SMITH SANDFORD D | Director | Sell | S | 95.00 | 2,502 | 237,690 | 0 | 2.5 K to 0 (-100.00 %) |
Oct 31 2013 | AEGR | Aegerion Pharmaceu ... | SMITH SANDFORD D | Director | Buy | M | 15.00 | 2,502 | 37,530 | 2,502 | 0 to 2.5 K |
Oct 16 2013 | AEGR | Aegerion Pharmaceu ... | Sumeray Mark | Chief Medical Offic ... | Option Exercise | M | 13.01 | 2,000 | 26,020 | 130,500 | |
Oct 16 2013 | AEGR | Aegerion Pharmaceu ... | Sumeray Mark | Chief Medical Offic ... | Sell | S | 80.71 | 1,000 | 80,709 | 0 | 1,000 to 0 (-100.00 %) |
Oct 16 2013 | AEGR | Aegerion Pharmaceu ... | Sumeray Mark | Chief Medical Offic ... | Sell | S | 79.95 | 1,000 | 79,950 | 1,000 | 2 K to 1,000 (-50.00 %) |
Oct 16 2013 | AEGR | Aegerion Pharmaceu ... | Sumeray Mark | Chief Medical Offic ... | Buy | M | 13.01 | 2,000 | 26,020 | 2,000 | 0 to 2 K |
Oct 08 2013 | AEGR | Aegerion Pharmaceu ... | Sumeray Mark | Chief Medical Offic ... | Option Exercise | M | 13.01 | 3,500 | 45,535 | 132,500 | |
Oct 08 2013 | AEGR | Aegerion Pharmaceu ... | Sumeray Mark | Chief Medical Offic ... | Sell | S | 94.81 | 700 | 66,368 | 0 | 700 to 0 (-100.00 %) |
Oct 08 2013 | AEGR | Aegerion Pharmaceu ... | Sumeray Mark | Chief Medical Offic ... | Sell | S | 93.23 | 1,265 | 117,932 | 700 | 2 K to 700 (-64.38 %) |
Oct 08 2013 | AEGR | Aegerion Pharmaceu ... | Sumeray Mark | Chief Medical Offic ... | Sell | S | 92.37 | 1,535 | 141,786 | 1,965 | 3.5 K to 2 K (-43.86 %) |
Oct 08 2013 | AEGR | Aegerion Pharmaceu ... | Sumeray Mark | Chief Medical Offic ... | Buy | M | 13.01 | 3,500 | 45,535 | 3,500 | 0 to 3.5 K |
Oct 08 2013 | AEGR | Aegerion Pharmaceu ... | Fraser Craig | Pres., US/Int. Comm ... | Option Exercise | M | 13.01 | 20,000 | 260,200 | 80,000 | |
Oct 08 2013 | AEGR | Aegerion Pharmaceu ... | Fraser Craig | Pres., US/Int. Comm ... | Sell | S | 96.25 | 100 | 9,625 | 0 | 100 to 0 (-100.00 %) |
Oct 08 2013 | AEGR | Aegerion Pharmaceu ... | Fraser Craig | Pres., US/Int. Comm ... | Sell | S | 94.82 | 3,800 | 360,329 | 100 | 3.9 K to 100 (-97.44 %) |
Oct 08 2013 | AEGR | Aegerion Pharmaceu ... | Fraser Craig | Pres., US/Int. Comm ... | Sell | S | 93.18 | 7,092 | 660,857 | 3,900 | 11 K to 3.9 K (-64.52 %) |